Cho SK, et al. - This study involves estimation of the incidence of malignancy in early rheumatoid arthritis (RA) patients. Researchers also assessed the relative risk of malignancy with use of biologic disease-modifying anti-rheumatic drugs (bDMARDs). With the use of bDMARD in early RA patients, reduction in the overall risk of developing malignancies was noted, however, the risk of developing hematologic malignancies remained uninfluenced.